ACC.19: 3 Studies in Cardioprotection
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.
Recent Videos
Related Content
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
January 16th 2025Article
The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.
